Perrigo Prepares To Pioneer US OTC Birth Control Sales As ‘Supply Chain Reinvention’ Continues

Firm reports Q2 net sales up 6.4% to $1.2bn while organic measure was 0.8% growth after a 2.7 percentage point drag from SKU prioritization moves. Investment planned over second half to prepare for launch of Opill sales.